Congke G. Zhao

Changsha, 410013, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Identification of an Hsp110/HDAC6 Dual-Target Inhibitor for the Effective Treatment of Pulmonary Arterial Hypertension via Synergistic Blockade of Vascular Remodeling.

Identification of an Hsp110/HDAC6 Dual-Target Inhibitor for the Effective Treatment of Pulmonary Arterial Hypertension via Synergistic Blockade of Vascular Remodeling.

Journal: Journal of medicinal chemistry

Published: May 11, 2026

Identification of Nitric Oxide-Donating Lenumlostat Derivatives with Dual Activities of Extracellular Matrix Dysregulation Inhibition and Pulmonary Vasodilation for the Treatment of Pulmonary Arterial Hypertension.

Identification of Nitric Oxide-Donating Lenumlostat Derivatives with Dual Activities of Extracellular Matrix Dysregulation Inhibition and Pulmonary Vasodilation for the Treatment of Pulmonary Arterial Hypertension.

Journal: Journal of medicinal chemistry

Published: April 22, 2026

Design and Optimization of LOXL2 and sGC Dual-Target Regulators Targeting Extracellular Matrix Dysregulation and Vasodilation for the Treatment of Pulmonary Arterial Hypertension.

Design and Optimization of LOXL2 and sGC Dual-Target Regulators Targeting Extracellular Matrix Dysregulation and Vasodilation for the Treatment of Pulmonary Arterial Hypertension.

Journal: Journal of medicinal chemistry

Published: December 13, 2025

Corrigendum to "Discovery of Artesunate (ARS) PROTACs as GPX4 protein degraders for the treatment of bladder cancer" [Eur. J. Med. Chem. 293 (2025) 117710].

Corrigendum to "Discovery of Artesunate (ARS) PROTACs as GPX4 protein degraders for the treatment of bladder cancer" [Eur. J. Med. Chem. 293 (2025) 117710].

Journal: European journal of medicinal chemistry

Published: September 10, 2025

Discovery of Artesunate (ARS) PROTACs as GPX4 protein degraders for the treatment of bladder cancer.

Discovery of Artesunate (ARS) PROTACs as GPX4 protein degraders for the treatment of bladder cancer.

Journal: European journal of medicinal chemistry

Published: December 06, 2024

Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics.

Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics.

Journal: Drug discovery today

Published: November 17, 2024

A novel pyridine-2-one AMPK inhibitor: Discovery, mechanism, and in vivo evaluation in a hypoxic pulmonary arterial hypertension rat model.

A novel pyridine-2-one AMPK inhibitor: Discovery, mechanism, and in vivo evaluation in a hypoxic pulmonary arterial hypertension rat model.

Journal: European journal of medicinal chemistry

Published: November 02, 2024

Inhibition of breast cancer growth with AN-329, a novel Hsp110 inhibitor, by inactivating p-STAT3/c-Myc axis.

Inhibition of breast cancer growth with AN-329, a novel Hsp110 inhibitor, by inactivating p-STAT3/c-Myc axis.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: September 01, 2024

Design, synthesis and optimization of pyrazolo[3,4-b] pyridine derivatives as Hsp110-STAT3 interaction disruptors for the treatment of pulmonary arterial hypertension.

Design, synthesis and optimization of pyrazolo[3,4-b] pyridine derivatives as Hsp110-STAT3 interaction disruptors for the treatment of pulmonary arterial hypertension.

Journal: Bioorganic chemistry

Published: August 31, 2024

Discovery and Optimization of Hsp110 and sGC Dual-Target Regulators for the Treatment of Pulmonary Arterial Hypertension.

Discovery and Optimization of Hsp110 and sGC Dual-Target Regulators for the Treatment of Pulmonary Arterial Hypertension.

Journal: Journal of medicinal chemistry

Published: July 26, 2024

Allosteric site identification, virtual screening and discovery of a sulfonamide Hsp110-STAT3 interaction inhibitor for the treatment of hypoxic pulmonary arterial hypertension.

Allosteric site identification, virtual screening and discovery of a sulfonamide Hsp110-STAT3 interaction inhibitor for the treatment of hypoxic pulmonary arterial hypertension.

Journal: European journal of medicinal chemistry

Published: July 16, 2024

Heat shock protein 110: A novel candidate for disease diagnosis and targeted therapy.

Heat shock protein 110: A novel candidate for disease diagnosis and targeted therapy.

Journal: Drug discovery today

Published: July 04, 2024

Showing 1-12 of 19

Last Updated: 09/26/2026